Key clinical point: Napabucasin, a novel inhibitor of STAT3, inhibits growth and shows synergy with doxorubicin in DLBCL.
Major finding: Napabucasin exhibited potent cytotoxicity on DLBCL xenograft tumors without obvious drug toxicity in vivo.
Study details: A panel of cell lines were treated with napabucasin and assessed for growth, viability.
Disclosures: The authors declared that they had no conflicts of interest.
Li X et al. Cancer Letters. 2020; doi.org/10.1016/j.canlet.2020.07.032.